Improving outcomes and combating AMR by giving the best drug every time
iFAST is addressing the $4bn (& growing) Antimicrobial Susceptibility Testing (AST) market.
We have a test that is up to 10x faster and cheaper than the gold standard, delivering results in 4 hours for urine samples and 8 hours for sepsis, saving lives and reducing the spread of antimicrobial resistance.
iFAST selected for the Healthcare Innovation Consortium's AMR Innovation Programme
Bacteria are increasingly resistant to antibiotics – resistance levels are 20% - 98% and unpredictable. Current Antimicrobial Susceptibility Testing (AST) takes 48 -72 hours – patients deteriorate whilst waiting for the correct drug.
Prescribing inappropriate antibiotics leads to the spread of resistant infections, sepsis and death
Antimicrobial resistance (AMR) caused over 1 million deaths in 2019 – more than malaria or AIDS
iFAST reduces AST test time from 48+ to 4 hours
Blood/urine sample Incubated
Sample incubated for
a few hours then exposed to
range of antibiotics
Test itself takes
After a further 1 hour incubation, reader scans 5,000 individual bacteria
optimum antibiotic for clinician to prescribe
The Benefits of iFAST
Results in only 4 hours (urine)
– 8 hours (blood) from raw sample
Each reader performs
> 100 tests/day
Cheaper than current
gold standard methods
Small lab footprint
Reader is only 600x600mm
and fits neatly on a lab bench
Each sample analysed in less than a minute
The electrical properties of single bacteria are measured at high speed in a microfluidic chip.
Experienced and committed team
Research Systems available NOW, with clinical systems expected to launch next year.
To find out more
If you would like find out more please send us
an email and we will get in touch.
Find our presentation, nature paper below & synopsis for hospitals below.
We are thrilled with the outcome of our first two hospital evaluations with our iFAST demonstrator platform - the results are spectacular! Both trials were comparing the iFAST technology with the hospital current standard of care (disk diffusion), using patient blood samples.
Watch iFAST video - 3.5 mins
Watch iFAST video - 49 secs
On 16-17 November 2023 the sixth edition of ‘Emerging Antimicrobials and Diagnostics in AMR’ will take place at the iconic ‘De Bazel’ in the city centre of Amsterdam! Emerging Antimicrobials and Diagnostics in AMR (EADA) is the place where key players in research, business and funding of Antimicrobial resistance (AMR), come together with the aim to stimulate the development of antimicrobials and diagnostics for the global fight against AMR.
16.05 – 16th November
iFAST – High-throughput, cost-effective AST in 3 hours – Clinical data
Presented by Dr Toby King, CEO iFAST Diagnostics